JP2009509921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509921A5 JP2009509921A5 JP2008525977A JP2008525977A JP2009509921A5 JP 2009509921 A5 JP2009509921 A5 JP 2009509921A5 JP 2008525977 A JP2008525977 A JP 2008525977A JP 2008525977 A JP2008525977 A JP 2008525977A JP 2009509921 A5 JP2009509921 A5 JP 2009509921A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pain
- disorders
- disease
- neurological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims 5
- 208000009025 Nervous System Disease Diseases 0.000 claims 4
- 206010029305 Neurological disorder Diseases 0.000 claims 4
- 206010037175 Psychiatric disease Diseases 0.000 claims 4
- 206010057666 Anxiety disease Diseases 0.000 claims 3
- 208000008581 Brain Disease Diseases 0.000 claims 3
- 206010015037 Epilepsy Diseases 0.000 claims 3
- 206010028334 Muscle spasms Diseases 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000008839 post-traumatic stress disease Diseases 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010004938 Bipolar disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 206010027599 Migraine Diseases 0.000 claims 2
- 208000008085 Migraine Disorders Diseases 0.000 claims 2
- 206010033666 Panic disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 206010061920 Psychotic disease Diseases 0.000 claims 2
- 208000005809 Status Epilepticus Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 201000008895 mood disease Diseases 0.000 claims 2
- 201000001552 phobic disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000005298 Acute Pain Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000006752 Brain Edema Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000001187 Dyskinesias Diseases 0.000 claims 1
- 206010018075 Generalised anxiety disease Diseases 0.000 claims 1
- 208000004559 Hearing Loss Diseases 0.000 claims 1
- 206010011879 Hearing loss Diseases 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000004404 Intractable Pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010028302 Muscle disease Diseases 0.000 claims 1
- 206010052639 Nerve injury Diseases 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 206010029897 Obsessive thoughts Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038932 Retinopathy Diseases 0.000 claims 1
- 210000003625 Skull Anatomy 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000002512 Traumatic Stress Disorders Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 201000005913 acute stress disease Diseases 0.000 claims 1
- 230000003542 behavioural Effects 0.000 claims 1
- 201000006474 brain ischemia Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 230000035591 circadian rhythms Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 201000006529 generalized anxiety disease Diseases 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 201000010770 muscular disease Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 201000007196 sexual disease Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/028760 WO2006020879A1 (fr) | 2004-08-13 | 2005-08-12 | Composes a base d'isoindolone et leur utilisation comme potentialisateurs du recepteur metabotropique du glutamate |
| PCT/US2006/005247 WO2007021309A1 (fr) | 2005-08-12 | 2006-02-15 | Isoindolones substitués et leur utilisation comme potentiateurs métabotropiques du récepteur glutamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009509921A JP2009509921A (ja) | 2009-03-12 |
| JP2009509921A5 true JP2009509921A5 (fr) | 2009-04-23 |
Family
ID=36464390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525976A Expired - Fee Related JP5031745B2 (ja) | 2005-08-12 | 2006-02-15 | 代謝型グルタミン酸受容体増強性イソインドロン |
| JP2008525977A Pending JP2009509921A (ja) | 2005-08-12 | 2006-02-15 | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525976A Expired - Fee Related JP5031745B2 (ja) | 2005-08-12 | 2006-02-15 | 代謝型グルタミン酸受容体増強性イソインドロン |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP1912940A1 (fr) |
| JP (2) | JP5031745B2 (fr) |
| CN (2) | CN101309905A (fr) |
| WO (2) | WO2007021309A1 (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| US20080139846A1 (en) * | 2006-09-01 | 2008-06-12 | Astrazeneca Ab | New Process 298 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2008130853A1 (fr) * | 2007-04-17 | 2008-10-30 | Astrazeneca Ab | Hydrazides et leur utilisation en tant que potentialisateurs des récepteurs métabotropiques du glutamate |
| US20100197800A1 (en) * | 2007-04-23 | 2010-08-05 | Richard Friedman | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 |
| TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| WO2009004430A1 (fr) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate |
| TW200927731A (en) | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
| SA109300358B1 (ar) | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
| WO2010025890A1 (fr) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| CA2754688A1 (fr) | 2009-03-11 | 2010-09-16 | Msd K.K. | Nouveau derive d'isoindolin-1-one |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CA2760259C (fr) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | Derives de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2 |
| JP5634506B2 (ja) | 2009-05-12 | 2014-12-03 | ジャンセン ファーマシューティカルズ， インコーポレイテッド | １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
| BR112012007737A2 (pt) * | 2009-10-09 | 2015-09-15 | Celgene Corp | processos para a preparação de compostos de 2-(1-feniletil)isoindolin-1-ona |
| WO2011051490A2 (fr) | 2009-11-02 | 2011-05-05 | N.V. Organon | Dérivés hétérocycliques |
| RU2012134329A (ru) * | 2010-01-07 | 2014-02-20 | Астразенека Аб | Способ получения позитивного аллостерического модулятора метаботропных глутаматных рецепторов-874 |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
| JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| AR088320A1 (es) | 2011-10-14 | 2014-05-28 | Incyte Corp | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt |
| HUE031313T2 (hu) | 2011-10-28 | 2017-07-28 | Univ Vanderbilt | Szubsztituált 2-(4-heterociklilbenzil)izoindolin-1-on analógok mint muszkarin acetilkolin receptor M1 pozitív allosztérikus modulátorai |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| WO2015110435A1 (fr) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de sous-type 2 de récepteur glutamatergique métabotrope, et leur utilisation |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| SG11201803234TA (en) | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| CN108602805A (zh) | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂 |
| WO2017087808A1 (fr) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Composés hétérocycliques inhibant l'activité kinase de mnk utiles pour le traitement de divers cancers |
| CN105837557A (zh) * | 2016-05-05 | 2016-08-10 | 青岛辰达生物科技有限公司 | 一种用于治疗ii型糖尿病的阿格列汀的制备方法 |
| CN106279182B (zh) * | 2016-07-29 | 2019-06-07 | 中国药科大学 | 一种吡咯并[2，1-a]异吲哚酮类化合物及其合成方法 |
| EP3582776B1 (fr) | 2017-02-14 | 2023-11-08 | Effector Therapeutics, Inc. | Inhibiteurs de mnk à substitution de pipéridine et leurs procédés associés |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP3459939A1 (fr) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Nouveaux composés hétérocycliques comme modulateurs de mglur7 |
| TW202035405A (zh) | 2018-10-24 | 2020-10-01 | 美商伊凡克特治療公司 | Ｍｎｋ抑制劑的結晶形式 |
| WO2020102216A1 (fr) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Dérivés hétécycliques substitués utiles en tant qu'inhibiteurs de pi3k |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| WO2020102198A1 (fr) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Dérivés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k |
| CN110498759A (zh) * | 2019-09-12 | 2019-11-26 | 天津瑞岭化工有限公司 | 异吲哚啉酮类化合物的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE620654C (de) * | 1933-04-29 | 1935-10-24 | Smith & Sons Ltd S | Geschwindigkeitsanzeiger |
| US3579524A (en) * | 1968-06-05 | 1971-05-18 | Miles Lab | 2-aminoalkyl derivatives of phthalimidines |
| US3993617A (en) * | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
| DE3717561A1 (de) * | 1987-05-25 | 1988-12-08 | Thomae Gmbh Dr K | Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPH02184667A (ja) * | 1989-01-11 | 1990-07-19 | Meiji Seika Kaisha Ltd | Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤 |
| TW219935B (fr) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| RU2124511C1 (ru) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
| US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| CN1158264C (zh) * | 1997-11-21 | 2004-07-21 | Nps药物有限公司 | 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂 |
| KR100815772B1 (ko) * | 2000-02-29 | 2008-03-20 | 미쯔비시 웰 파마 가부시키가이샤 | 신규 고리상 아미드 유도체 |
| DE10031391A1 (de) * | 2000-07-03 | 2002-02-07 | Knoll Ag | Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie |
| ES2291329T3 (es) * | 2000-07-18 | 2008-03-01 | Dainippon Sumitomo Pharma Co., Ltd. | Inhibidores de la recaptacion de serotonina. |
| DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB0223232D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| US20070135485A1 (en) * | 2003-10-22 | 2007-06-14 | Gillig James R | Novel mch receptor antagonists |
| WO2005074643A2 (fr) * | 2004-01-30 | 2005-08-18 | Smithkline Beecham Corporation | Composes chimiques |
| AU2005219791B2 (en) * | 2004-03-05 | 2011-06-09 | Msd K.K. | Diaryl-substituted five-membered heterocycle derivative |
| EA014881B1 (ru) * | 2004-03-05 | 2011-02-28 | Ниссан Кемикал Индастриз, Лтд. | Производные замещенного алкилбензола |
| TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
-
2006
- 2006-02-15 EP EP06720759A patent/EP1912940A1/fr not_active Withdrawn
- 2006-02-15 JP JP2008525976A patent/JP5031745B2/ja not_active Expired - Fee Related
- 2006-02-15 JP JP2008525977A patent/JP2009509921A/ja active Pending
- 2006-02-15 CN CNA2006800353774A patent/CN101309905A/zh active Pending
- 2006-02-15 WO PCT/US2006/005247 patent/WO2007021309A1/fr active Application Filing
- 2006-02-15 WO PCT/US2006/005246 patent/WO2007021308A1/fr active Application Filing
- 2006-02-15 EP EP06720758A patent/EP1912939A1/fr not_active Withdrawn
- 2006-02-15 CN CNA2006800363117A patent/CN101277934A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509921A5 (fr) | ||
| JP2009509920A5 (fr) | ||
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| WO2009117515A8 (fr) | Nouveaux composés servant à traiter les maladies et troubles du système nerveux central | |
| MX2010001824A (es) | Heterociclos como moduladores de canal de potasio. | |
| NO20100078L (no) | (2S,3R)-N-(2-((3-pyridinyl)metyl)-1-azabicyklo[2.2.2]oct-3-yl)benzofuran-2-karboksamid, nye saltformer og deres anvendelse | |
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| EP2604602A4 (fr) | Dérivé d'hétéroaryl pyrazole | |
| NI200900131A (es) | Compuesto de [1,2,3]-benzotriazinona-3-. sustituid | |
| JP2013512926A5 (fr) | ||
| JP2013544277A5 (fr) | ||
| NZ600008A (en) | Multicyclic compounds and methods of use thereof | |
| HRP20140867T1 (hr) | Heterocikliäśki sulfonamidi, njihova upotreba i farmaceutski pripravci | |
| JP2012530129A5 (fr) | ||
| TW200745135A (en) | Therapeutic agents | |
| AU4327101A (en) | Aminoadamantane derivatives as therapeutic agents | |
| WO2006019886A3 (fr) | Pyrrolo(oxo)isoquinoleines utilisees comme ligands 5ht | |
| JP2008519056A5 (fr) | ||
| GB2462235A (en) | NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities | |
| JP2014500885A5 (fr) | ||
| TN2009000278A1 (en) | 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| JP2017502069A5 (fr) | ||
| RU2016132574A (ru) | Органические соединения | |
| WO2009001356A3 (fr) | Dérivés de l'acyl-urée et utilisations |